FILANA THERAPEUTICS, INC. (FLNA): restructuring charge — Cassava cuts workforce 33% after Phase 3 miss; REFOCUS-ALZ results due Q1/Q2 2025

FILANA THERAPEUTICS, INC.

Workforce reduction of 10 employees (33%) with ~$0.4M severance costs in Q1 2025.
Cash and cash equivalents ~$128.6M as of Dec 31, 2024 (unaudited).
Topline data from Phase 3 REFOCUS-ALZ study expected late Q1/early Q2 2025.
Halting planned biomarker analysis of additional plasma samples from prior Phase 2 studies.
RETHINK-ALZ study did not meet co-primary endpoints; REFOCUS-ALZ and OLE study discontinued.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

FILANA THERAPEUTICS, INC. announced a restructuring with charges of approximately $0.4 million (10 employees, a reduction of 33%).

Type: restructuring
Charge: approximately $0.4 million
Headcount: 10 employees, a reduction of 33%

Exact text from the filing

The Company estimates that it will incur approximately $0.4 million of one-time costs in connection with the Workforce Reduction, primarily related to severance payments.

View on SEC.gov

15 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001171843-25-000089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.